Takeda Stresses Orexin Commitment Despite Setback
Big Share Buyback As Q2 Reported
Fiscal Q2 figures in line with expectations but investors digest surprise trial halt and share buyback.
Fiscal Q2 figures in line with expectations but investors digest surprise trial halt and share buyback.